FIT 003
Alternative Names: FIT-003Latest Information Update: 29 Mar 2024
At a glance
- Originator Guangzhou FineImmune Biotechnology
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours